Bicycle Therapeutics PLCNASDAQ:BCYC
- LAST PRICE24.2200
- TODAY'S CHANGE (%)0.8100 (3.4601%)
- Bid / Lots24.2000/ 4
- Ask / Lots24.3000/ 3
- Open / Previous Close23.2000 / 23.4100
- Day Range
- 52 Week Range
- Volume54,961
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BCYC |
|---|---|---|
| 09:32 ET | 200 | 23.44 |
| 09:34 ET | 400 | 23.61 |
| 09:38 ET | 200 | 23.61 |
| 09:39 ET | 200 | 23.36 |
| 09:43 ET | 864 | 23.66 |
| 09:50 ET | 100 | 23.81 |
| 09:52 ET | 800 | 23.84 |
| 09:54 ET | 100 | 24.06 |
| 09:56 ET | 5112 | 23.87 |
| 09:57 ET | 5353 | 24.025 |
| 09:59 ET | 200 | 23.98 |
| 10:03 ET | 2100 | 24.06 |
| 10:06 ET | 100 | 24.065 |
| 10:08 ET | 802 | 24.27 |
| 10:10 ET | 462 | 24.28 |
| 10:12 ET | 1880 | 24.3 |
| 10:14 ET | 200 | 24.29 |
| 10:15 ET | 100 | 24.3 |
| 10:17 ET | 219 | 24.3281 |
| 10:19 ET | 100 | 24.26 |
| 10:21 ET | 100 | 24.37 |
| 10:24 ET | 100 | 24.37 |
| 10:26 ET | 400 | 24.41 |
| 10:28 ET | 1363 | 24.32 |
| 10:32 ET | 1215 | 24.23 |
| 10:35 ET | 8563 | 24.165 |
| 10:37 ET | 4733 | 24.165 |
| 10:39 ET | 3141 | 24 |
| 10:44 ET | 3474 | 24.19 |
| 10:46 ET | 2525 | 24.23 |
| 10:48 ET | 100 | 24.22 |
| 10:50 ET | 300 | 24.25 |
Apr 24, 2024
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting, from 10:05AM ET on Wednesday Apr 24, 2024 by Dow Jones
10:05AM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 10, 2024
DJ Bicycle Therapeutics Price Target Maintained With a $43.00/Share by Needham, from 5:32AM ET on Wednesday Apr 10, 2024 by Dow Jones
5:32AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 2, 2024
Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference, from 7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bicycle Therapeutics PLC | 888.8M | -4.7x | --- |
Relay Therapeutics Inc | 872.1M | -2.4x | --- |
Tango Therapeutics Inc | 839.9M | -7.3x | --- |
Immunome Inc | 825.0M | -4.2x | --- |
SS Innovations International Inc | 851.9M | -36.7x | --- |
Centessa Pharmaceuticals PLC | 931.8M | -5.9x | --- |
Company Information
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.
Contact Information
- Headquarters
- Blocks A & B, Portway Building, Granta PCAMBRIDGE, United Kingdom CB21 6GS
- Phone
- 122-326-1503
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Pierre Legault
- Chief Executive Officer, Executive Director
- Kevin Lee
- Chief Financial Officer, Principal Financial Officer
- Alethia Young
- Chief Operating Officer
- Alistair Milnes
- Chief Technology Officer
- Michael Skynner
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $888.8M |
|---|---|
Revenue (TTM) | $27.0M |
Shares Outstanding | 38.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.90 |
EPS | $-5.13 |
Book Value | $8.74 |
P/E Ratio | -4.7x |
Price/Sales (TTM) | 32.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -704.13% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
